[(3S)-3-(N-benzyloxycarbonyl)amino-3-methoxycarbonylpropyl][(5-nitrothiophen-2-yl)hydroxymethyl]phosphinic acid | 936234-77-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(3S)-3-(N-benzyloxycarbonyl)amino-3-methoxycarbonylpropyl][(5-nitrothiophen-2-yl)hydroxymethyl]phosphinic acid
• 英文别名: (3S)-2-[(((3-(N-benzyloxycarbonyl)amino-3-methoxycarbonyl)propyl)(hydroxy)phosphinyl)-hydroxymethyl]-5-nitrothiophene；[hydroxy-(5-nitrothiophen-2-yl)methyl]-[(3S)-4-methoxy-4-oxo-3-(phenylmethoxycarbonylamino)butyl]phosphinic acid
• CAS: 936234-77-4
• 化学式: C₁₈H₂₁N₂O₉PS
• 分子量: 472.413
• InChiKey: QMDXHIMCGYKMGF-CWQZNGJJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  196
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  [(3S)-3-(N-benzyloxycarbonyl)amino-3-methoxycarbonylpropyl][(5-nitrothiophen-2-yl)hydroxymethyl]phosphinic acid 在 盐酸 作用下， 反应 5.0h， 以3.2 mg的产率得到[(3S)-3-amino-3-carboxypropyl][(5-nitrothiophen-2-yl)hydroxymethyl]phosphinic acid
  参考文献：
  名称：

  Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites

  摘要：

  A group III metabotropic glutamate (mGlu) receptor agonist (PCEP) was identified by virtual HTS. This orthosteric ligand is composed by an L-AP4-derived fragment that mimics glutamate and a chain that binds into a neighboring pocket, offering possibilities to improve affinity and selectivity. Herein we describe a series of derivatives where the distal chain is replaced by an aromatic or heteroaromatic group. Potent agonists were identified, including some with a mGlu(4) subtype preference, e.g., 17m (LSP1-2111) and 16g (LSP4-2022). Molecular modeling suggests that aromatic functional groups may bind at either one of the two chloride regulatory sites. These agonists may thus be considered as particular bitopic/dualsteric ligands. 17m was shown to reduce GABAergic synaptic transmission at striatopallidal synapses. We now demonstrate its inhibitory effect at glutamatergic parallel fiber-Purkinje cell synapses in the cerebellar cortex. Although these ligands have physicochemical properties that are markedly different from typical CNS drugs, they hold significant therapeutic potential.

  DOI：

  10.1021/acs.jmedchem.7b01438
• 作为产物：
  描述：

  (S)-2-(苄氧羰氨基)-3-丁烯酸甲酯 在 N,O-双三甲硅基乙酰胺 、 次磷酸 作用下， 以 二氯甲烷 为溶剂， 生成 [(3S)-3-(N-benzyloxycarbonyl)amino-3-methoxycarbonylpropyl][(5-nitrothiophen-2-yl)hydroxymethyl]phosphinic acid
  参考文献：
  名称：

  Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites

  摘要：

  A group III metabotropic glutamate (mGlu) receptor agonist (PCEP) was identified by virtual HTS. This orthosteric ligand is composed by an L-AP4-derived fragment that mimics glutamate and a chain that binds into a neighboring pocket, offering possibilities to improve affinity and selectivity. Herein we describe a series of derivatives where the distal chain is replaced by an aromatic or heteroaromatic group. Potent agonists were identified, including some with a mGlu(4) subtype preference, e.g., 17m (LSP1-2111) and 16g (LSP4-2022). Molecular modeling suggests that aromatic functional groups may bind at either one of the two chloride regulatory sites. These agonists may thus be considered as particular bitopic/dualsteric ligands. 17m was shown to reduce GABAergic synaptic transmission at striatopallidal synapses. We now demonstrate its inhibitory effect at glutamatergic parallel fiber-Purkinje cell synapses in the cerebellar cortex. Although these ligands have physicochemical properties that are markedly different from typical CNS drugs, they hold significant therapeutic potential.

  DOI：

  10.1021/acs.jmedchem.7b01438

文献信息

• Hypophosphorous Acid Derivatives and their Therapeutical Applications
  申请人：Acher Francine

  公开号：US20090170813A1

  公开（公告）日：2009-07-02

  Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, β, or a β, g-cyclic amino acid; .R 1 is H or R, R being an hydroxy or a carboxy protecting group; .Z is H or an amino protecting group R′, benzyl oxycarbonyl, benzyl or benzyl substituted; .E is H or a C1-C3 alkyl, aryl, an hydrophobic group; .R 2 is selected in the group comprising: D-CH(R 6 )—C—(R 7 ,R 8 ), (R 11 ,R 12 )CH—C(R 9 ,R 10 ), D-CH(OH), D-[C(R 13 ,R 14 )] n3 —, C[(R 15 ,R 16 ,R 17 )] n4 , D-CH 2 , (R 18 )CH═C(R 19 ), D-(M 1 ) n6 —CO, Formula (II), PO(OH) 2 —CH 2 or (PO(OH) 2 —CH 2 ), (COOH—CH 2 )—CH 2 , with -D=H, OH, OR, (CH 2 ) n2 OH, (CH 2 ) n1 OR, COOH, COOR, (CH 2 ) n2 COOH, (CH 2 ) n1 COOR, SR, S(OR), SO 2 R, NO 2 , heteroaryl, C 1 -C 3 alkyl, cycloalkyl, heterocycloalkyl, (CH 2 ) n2 -alkyl, (COOH,NH 2 )—(CH 2 ) u1 -cyclopropyl-(CH 2 ) u2 —, CO—NH-alkyl, Ar, (CH 2 ) n2 —Ar, CO—NH—Ar; —R 3 to R 19 being H, OH, OR, (CH 2 ) n2 OH, (CH 2 ) n1 OR, COOH, COOR, (CH 2 ) n2 COOH, (CH 2 ) n1 COOR, C 1 -C 3 alkyl, cycloalkyl, (CH 2 )n1-alkyl, aryl, (CH 2 )n1-aryl, halogen, CF 3 , SO 3 H, (CH 2 ) x PO 3 H 2 , with x=0, 1 or 2, B(OH) 2 , Formula (III), NO 2 , SO 2 NH 2 , SO 2 NHR; SR, S(O)R, SO 2 R, benzyl; -M 1 is an alkylene or arylene group; -n1=1, 2 or 3, n2=1, 2 or 3, n3=0, 1, 2 or 3 and n4=1, 2 or 3, n5=1, 2 or 3, n6=0 or 1, u1 and u2, identical or different=0, 1 or 2, with the proviso that Formula (I) does not represent the racemic (3R,S) and the enantiomeric form (3R) of 3 amino,3-carboxy-propyl-2′-carboxy-ethylphosphinic acid; 3 amino,3-carboxy-propyl-4′carboxy,2′carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl-2′carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl-3′amino, 3′carboxy-propylylphosphinic acid; and 3 amino,3-carboxypropyl-7′amino-2′, 7′-dicarboxyheptylphosphinic acid, said hypophosphorous acid derivatives being diasteroisomers or enantiomers. Application as drugs.

  含有Formula (I)的次磷酸衍生物，其中.M是[C(R3,R4)]n1-C(E,COOR1,N(H,Z))基团，或者是一个可选择取代的Ar—CH(COOR1,N(H,Z))基团，或者是α，β或αβ，γ-环氨基酸；.R1是H或R，R是一个羟基或羧基保护基团；.Z是H或氨基保护基团R′，苄氧羰基，苄基或苄基取代；.E是H或C1-C3烷基，芳基，疏水基团；.R2是从以下群体中选择的：D-CH(R6)—C—(R7,R8)，(R11,R12)CH—C(R9,R10)，D-CH(OH)，D-[C(R13,R14)]n3—，C[(R15,R16,R17)]n4，D-CH2，(R18)CH═C(R19)，D-(M1)n6—CO，Formula (II)，PO(OH)2—CH2或(PO(OH)2—CH2)，(COOH—CH2)—CH2，其中-D=H，OH，OR，(CH2)n2OH，(CH2)n1OR，COOH，COOR，(CH2)n2COOH，(CH2)n1COOR，SR，S(OR)，SO2R，NO2，杂环芳基，C1-C3烷基，环烷基，杂环烷基，(CH2)n2-烷基，(COOH,NH2)—(CH2)u1-环丙基-(CH2)u2—，CO—NH-烷基，Ar，(CH2)n2—Ar，CO—NH—Ar；—R3到R19为H，OH，OR，(CH2)n2OH，(CH2)n1OR，COOH，COOR，(CH2)n2COOH，(CH2)n1COOR，C1-C3烷基，环烷基，(CH2)n1-烷基，芳基，(CH2)n1-芳基，卤素，CF3，SO3H，(CH2)xPO3H2，其中x=0，1或2，B(OH)2，Formula (III)，NO2，SO2NH2，SO2NHR；SR，S(O)R，SO2R，苄基；-M1是一个烷基或芳基基团；-n1=1，2或3，n2=1，2或3，n3=0，1，2或3，n4=1，2或3，n5=1，2或3，n6=0或1，u1和u2，相同或不同=0，1或2，但Formula (I)不代表3-氨基，3-羧基-丙基-2′-羧基-乙磷酸的消旋体(3R,S)和对映体形式(3R)；3-氨基，3-羧基-丙基-4′羧基，2′羧基-丁酰磷酸；3-氨基，3-羧基-丙基-2′羧基-丁酰磷酸；3-氨基，3-羧基-丙基-3′氨基，3′羧基-丙基磷酸；和3-氨基，3-羧基丙基-7′氨基-2′，7′-二羧基庚基磷酸，所述的次磷酸衍生物为二对映异构体或对映体。用作药物的应用。
• [EN] HYPOPHOSPHOROUS ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS<br/>[FR] DERIVES ACIDES HYPOPHOSPHORES ET APPLICATIONS THERAPEUTIQUES
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2007052169A2

  公开（公告）日：2007-05-10

  [EN] Hypophosphorous acid derivatives having Formula (I) wherein . M is a [C(R3,R4)]n1 - C(E,COOR1, N(H, Z)) group, or an optionally substituted Ar-CH(COOR1, N(H, Z)) group, or an a, ß, or a ß, g-cyclic aminoacid; . R₁ is H or R, R being an hydroxy or a carboxy protecting group; . Z is H or an amino protecting group R', benzyl oxycarbonyl, benzyl or benzyl substituted; . E is H or a C1-C3 alkyl, aryl, an hydrophobic group; . R₂ is selected in the group comprising: D-CH(R₆)- C-(R₇, R₈), (R₁₁,R₁₂)CH- C(R₉, R₁₀), D - CH(OH), D- [C(R₁₃, R₁₄)]_n3 -, C[(R₁₅, R₁₆, R₁₇)]_n4, D-CH₂, (R₁₈)CH = C(R₁₉), D-(M₁)_n6-CO, Formula (II), PO(OH)₂-CH₂ or (PO(OH)₂-CH₂), (COOH-CH₂)-CH₂, with - D = H, OH, OR, (CH₂)_n2OH, (CH₂)_n1OR, COOH, COOR, (CH₂)_n2COOH, (CH₂)_n1COOR, SR, S(OR), SO₂R, NO₂, heteroaryl, C₁-C₃ alkyl, cycloalkyl, heterocycloalkyl, (CH₂)_n2-alkyl, (COOH, NH₂)-(CH₂)_u1-cyclopropyl-(CH₂)_u2-, CO-NH-alkyl, Ar, (CH₂)_n2-Ar, CO-NH-Ar; - R₃ to R₁₉ being H, OH, OR, (CH₂)_n2OH, (CH₂)_n1OR, COOH, COOR, (CH₂)_n2COOH, (CH₂)_n1COOR, C₁-C₃ alkyl, cycloalkyl, (CH₂)n1-alkyl, aryl, (CH₂)n1-aryl, halogen, CF₃, SO₃H, (CH₂)_x PO₃H₂, with x = 0, 1 or 2, B(OH)₂ , Formula (III), NO₂ , SO₂NH₂ , SO₂NHR; SR, S(O)R, SO₂R, benzyl; - M₁ is an alkylene or arylene group; - n1= 1, 2 or 3, n2= 1, 2 or 3, n3= 0, 1, 2 or 3 and n4= 1, 2 or 3, n5= 1,2 or 3, n6= 0 or 1, u1 and u2, identical or different = 0,1 or 2, with the proviso that Formula (I) does not represent the racemic (3R, S) and the enantiomeric form (3R) of 3 amino,3-carboxy-propyl-2'-carboxy-ethylphosphinic acid; 3 amino,3-carboxy-propyl- 4'carboxy,2'carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl- 2'carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl- 3'amino, 3'carboxy-propylylphosphinic acid; and 3 amino,3-carboxypropyl -7'amino-2', 7'-dicarboxyheptylphosphinic acid, said hypophosphorous acid derivatives being diasteroisomers or enantiomers. Application as drugs.
  [FR] Cette invention concerne des dérivés acides hypophosphorés représentés par la formule (I). Dans cette formule, M est un groupe [C(R3,R4)]n1 - C(E,COOR1, N(H, Z)), ou un groupe Ar-CH(COOR1, N(H, Z)) éventuellement substitué, ou un acide aminé a, ß, ou g-cyclique; . R₁ est H ou R, R étant un groupe protecteur hydroxy ou carboxy; . Z est H ou un groupe amino protecteur R', benzyl oxycarbonyl, benzyle ou substitué benzyle; E est H ou un C1-C3 alkyle, aryle, un groupe hydrophobe; . R2 est pris dan le groupe comprenant: D-CH(R₆)- C-(R₇, R₈), (R₁₁,R₁₂)CH- C(R₉, R₁₀), D - CH(OH), D- [C(R₁₃, R₁₄)]_n3 -, C[(R₁₅, R₁₆, R₁₇)]_n4, D-CH₂, (R₁₈)CH = C(R₁₉), D-(M₁)_n6-CO, PO(OH)2-CH₂ ou (PO(OH)₂-CH₂), (COOH-CH₂)-CH₂, avec - D = H, OH, OR, (CH₂)_n2OH, (CH₂)_n1OR, COOH, COOR, (CH₂)_n2COOH, (CH₂)_n1COOR, SR, S(OR), SO₂R, NO₂, hétéroaryle, C1-C3 alkyle, cycloalkyle, hétérocycloalkyle, (CH₂)_n2-alkyle, (COOH, NH₂)-(CH₂)_u1-cyclopropyl-(CH₂)_u2-, CO-NH-alkyle, Ar, (CH₂)_n2-Ar, CO-NH-Ar; - R₃ à R₁₉ étant H, OH, OR, (CH₂)_n2OH, (CH₂)_n1OR, COOH, COOR, (CH₂)_n2COOH, (CH₂)_n1COOR, C₁-C₃ alkyle, cycloalkyle, (CH₂)n1-alkyle, aryle, (CH₂)n1-aryle, halogène, CF₃, SO₃H, (CH₂)_x PO₃H₂, avec x = 0, 1 ou 2, B(OH)₂,, NO₂, SO₂NH₂, SO₂NHR; SR, S(O)R, SO₂R, benzyle; - M₁ est un groupe alkylène ou arylène; - n1= 1, 2 ou 3, n2= 1, 2 ou 3, n3= 0, 1, 2 ou 3 et n4= 1, 2 ou 3, n5= 1,2 ou 3, n6= 0 or 1, u1 and u2, identiques ou différents = 0,1 ou 2, à condition quela formule (I) ne représenter pas la forme racémique (3R, S) ni la forme énantiomère (3R) de 3 amino,3-carboxy-propyl-2'-carboxy-éthylphosphinique acide; 3 amino,3-carboxy-propyl- 4'carboxy,2'carboxy-butanoylphosphinique acide; 3 amino,3-carboxy-propyl- 2'carboxy-butanoylphosphinique acide; 3 amino,3-carboxy-propyl- 3'amino, 3'carboxy-propylylphosphinique acide; and 3 amino,3-carboxypropyl -7'amino-2', 7'-dicarboxyheptylphosphinique acide, lesdits dérivées acides hypophosphorés étant des diastero-isoméres ou des énantiomères. Cette invention concerne également l'application de ces dérivés en tant que médicaments.
• Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites
  作者：Chelliah Selvam、Isabelle A. Lemasson、Isabelle Brabet、Nadia Oueslati、Berin Karaman、Alexandre Cabaye、Amélie S. Tora、Bruno Commare、Tiphanie Courtiol、Sara Cesarini、Isabelle McCort-Tranchepain、Delphine Rigault、Laetitia Mony、Thomas Bessiron、Heather McLean、Frédéric R. Leroux、Françoise Colobert、Hervé Daniel、Anne Goupil-Lamy、Hugues-Olivier Bertrand、Cyril Goudet、Jean-Philippe Pin、Francine C. Acher

  DOI：10.1021/acs.jmedchem.7b01438

  日期：2018.3.8

  A group III metabotropic glutamate (mGlu) receptor agonist (PCEP) was identified by virtual HTS. This orthosteric ligand is composed by an L-AP4-derived fragment that mimics glutamate and a chain that binds into a neighboring pocket, offering possibilities to improve affinity and selectivity. Herein we describe a series of derivatives where the distal chain is replaced by an aromatic or heteroaromatic group. Potent agonists were identified, including some with a mGlu(4) subtype preference, e.g., 17m (LSP1-2111) and 16g (LSP4-2022). Molecular modeling suggests that aromatic functional groups may bind at either one of the two chloride regulatory sites. These agonists may thus be considered as particular bitopic/dualsteric ligands. 17m was shown to reduce GABAergic synaptic transmission at striatopallidal synapses. We now demonstrate its inhibitory effect at glutamatergic parallel fiber-Purkinje cell synapses in the cerebellar cortex. Although these ligands have physicochemical properties that are markedly different from typical CNS drugs, they hold significant therapeutic potential.